Profile
Jonas Hallén is the Chief Medical & Development Officer and founder of Arxx Therapeutics AS, which is founded in 2019.
He is also the Director of Nadeno Nanoscience AS, where he currently works.
Dr. Hallén is also the founder of Calluna Pharma, Inc.
Jonas Hallén active positions
| Companies | Position | Start |
|---|---|---|
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Founder | 2019-10-31 |
Nadeno Nanoscience AS
 Nadeno Nanoscience AS BiotechnologyHealth Technology Nadeno Nanoscience AS is a company based in Trondheim, Norway. Nadeno is a Sintef spin-off that specializes in nanotechnology drug delivery platforms. The Norwegian company has developed a platform that focuses on unleashing the potential of hard-to-deliver hydrophobic small molecule drugs. The company's technology is designed to address the majority of failures in drug delivery. The company was founded by Annbjørg Falck and Yrr Mørch, with Annbjørg Falck serving as CEO since incorporation. | Director/Board Member | 2022-10-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
Nadeno Nanoscience AS
Nadeno Nanoscience AS BiotechnologyHealth Technology Nadeno Nanoscience AS is a company based in Trondheim, Norway. Nadeno is a Sintef spin-off that specializes in nanotechnology drug delivery platforms. The Norwegian company has developed a platform that focuses on unleashing the potential of hard-to-deliver hydrophobic small molecule drugs. The company's technology is designed to address the majority of failures in drug delivery. The company was founded by Annbjørg Falck and Yrr Mørch, with Annbjørg Falck serving as CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Jonas Hallén
